Colchicine formulation switching and escalation to anti-IL-1 therapy in familial Mediterranean fever: A single-center real-world study Cambio de formulación de colchicina y escalada a terapia anti-IL-1 en la fiebre mediterránea familiar: estudio en vida real unicéntrico
Medicina Clinica, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Basım Tarihi: 2026
- Doi Numarası: 10.1016/j.medcli.2026.107673
- Dergi Adı: Medicina Clinica
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, DIALNET
- Anahtar Kelimeler: Anti-IL1 therapy, Colchicina, Colchicine, Familial Mediterranean fever (FMF), Fiebre mediterránea familiar, GenesMEFV, MEFV genes, Terapia anti-IL-1
- Akdeniz Üniversitesi Adresli: Evet
Özet
Objective: To evaluate the usage of colchicine formulations and anti-IL-1 therapy, identify the clinical and genetic factors associated with treatment escalation, and detail the reasons for colchicine formulation switching in patients with familial Mediterranean fever (FMF). Methods: This retrospective cohort with a cross-sectional assessment enrolled 128 patients diagnosed with FMF based on the Tel Hashomer criteria. To detect of the efficacy and the causes of switching among colchicine formulations and anti-interleukin-1 (IL-1) therapeutic interventions, comprehensive clinical, laboratory, and genetic profiles were systematically re-evaluated for all participants. Results: A total of 128 patients were analyzed, of whom 80 (62.5%) were female, with a mean age of 37.8±12.9 years. 84 (65.6%) patients were receiving coated colchicine, 33 (26%) were on compressed colchicine, and 11 were treated with anti-interleukin-1 (IL-1) agents when data was collected. A transition from coated to compressed colchicine was performed in 44 patients. The primary indications for this switch included inadequate clinical response in 25 (56.8%) patients, colchicine intolerance in 9 (20.4%), and physician preference in 10 (22.7%). Analysis of the allelic distribution revealed that the M694V mutation was present in 59.6% of all patients with FMF. However, in patients requiring anti-IL-1 agents—typically indicating a more severe or colchicine-resistant disease course—the prevalence of this mutation rose to 83.3%. Similarly, the rate of M694V homozygosity in the anti-IL-1 subgroup was nearly threefold higher than that of the general study group (50.0% vs. 18.3%, respectively). Conclusion: Optimizing colchicine delivery by transitioning to compressed formulations appears to provide a feasible intermediary step prior to initiating anti-IL-1 agents in FMF management. While Exon 10 mutations, particularly M694V, appear more frequent in patients requiring anti-IL-1 agents, prospective studies and cost-effectiveness analyses are warranted to confirm these findings.